Moleculin Biotech (NASDAQ:MBRX) has completed patient enrollment in its proof-of-concept trial of WP1220 for the treatment of cutaneous T-cell lymphoma (CTCL).
WP1220 is a topical treatment designed to inhibit p-STAT3, the activated form of the oncogenic transcription factor, STAT3, while stimulating the patient’s natural immune response.
“We believe there continues to be an unmet need for an improved topical therapy for Stage one-to-three CTCL skin lesions, especially one that may avoid significant unwanted side effects,” Walter Klemp, Moleculin’s chairman and CEO, said in a statement.
“CTCL is known to frequently involve the upregulation of the activated form of STAT3, which has been linked to a range of tumor-related transcriptional activity. This proof-of-concept, if successful, could be an important first demonstration of a therapeutic effect in humans from such a p-STAT3 inhibitor,” he added.
Moleculin expects to report results from the trial by the end of 2019.
